...continued from part 1 of 2...

 Bezard E, et al.           
Compensatory mechanisms in experimental and human parkinsonism: towards a
dynamic approach.
Prog Neurobiol. 1998 Jun; 55(2): 93-116.
PMID: 9618745; UI: 98282467.

 Malapani C, et al.           
Coupled Temporal Memories in Parkinson's Disease. A Dopamine-Related
Dysfunction.
J Cogn Neurosci. 1998 May 22; 10(3): 316-331.
PMID: 9618592.

 Ingham CA, et al.           
Plasticity of synapses in the rat neostriatum after unilateral lesion of the
nigrostriatal dopaminergic pathway.
J Neurosci. 1998 Jun 15; 18(12): 4732-4743.
PMID: 9614247; UI: 98279083.

 Knopman DS.           
The initial recognition and diagnosis of dementia.
Am J Med. 1998 Apr 27; 104(4A): 2S-12S. Review.
PMID: 9617846; UI: 98278408.

 Glozman JM, et al.           
Scale of quality of life of care-givers.
J Neurol. 1998 May; 245 Suppl 1: S39-S41.
PMID: 9617723; UI: 98280717.

 Martinez-Martin P, et al.           
Quality of life in Parkinson's disease: validation study of the PDQ-39 Spanish
version.
J Neurol. 1998 May; 245 Suppl 1: S34-S38.
PMID: 9617722; UI: 98280716.

 Grandas F, et al.           
Quality of life in patients with Parkinson's disease who transfer from
standard levodopa to Sinemet CR: the STAR study. The STAR Multicenter Study
Group.
J Neurol. 1998 May; 245 Suppl 1: S31-S33.
PMID: 9617721; UI: 98280715.

 Wasielewski PG, et al.           
Quality of life and Parkinson's disease: the CR FIRST Study.
J Neurol. 1998 May; 245 Suppl 1: S28-S30.
PMID: 9617720; UI: 98280714.

 Henneberg A.           
Additional therapies in Parkinson's disease patients: useful tools for the
improvement of the quality of life or senseless loss of resources?
J Neurol. 1998 May; 245 Suppl 1: S23-S27.
PMID: 9617719; UI: 98280713.

 MacMahon DG, et al.           
Practical approach to quality of life in Parkinson's disease: the nurse's
role.
J Neurol. 1998 May; 245 Suppl 1: S19-S22.
PMID: 9617718; UI: 98280712.

 Stocchi F, et al.           
Sleep disorders in Parkinson's disease.
J Neurol. 1998 May; 245 Suppl 1: S15-S18.
PMID: 9617717; UI: 98280711.

 Peto V, et al.           
PDQ-39: a review of the development, validation and application of a
Parkinson's disease quality of life questionnaire and its associated measures.
J Neurol. 1998 May; 245 Suppl 1: S10-S14.
PMID: 9617716; UI: 98280710.

 Baker MG.           
From the moment of diagnosis.
J Neurol. 1998 May; 245 Suppl 1: S7-S9.
PMID: 9617715; UI: 98280709.

 Martinez-Martin P.           
An introduction to the concept of "quality of life in Parkinson's disease".
J Neurol. 1998 May; 245 Suppl 1: S2-S6.
PMID: 9617714; UI: 98280708.

 McGeer EG, et al.           
The future use of complement inhibitors for the treatment of neurological
diseases.
Drugs. 1998 Jun; 55(6): 739-746.
PMID: 9617589; UI: 98280583.

 Schrag AE, et al.           
The safety of ropinirole, a selective nonergoline dopamine agonist, in
patients with Parkinson's disease.
Clin Neuropharmacol. 1998 May; 21(3): 169-175.
PMID: 9617508; UI: 98280502.

 van der Geest R, et al.           
Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine
in patients with idiopathic Parkinson's disease.
Clin Neuropharmacol. 1998 May; 21(3): 159-168.
PMID: 9617507; UI: 98280501.

 van Laar T, et al.           
Stepwise intravenous infusion of apomorphine to determine the therapeutic
window in patients with Parkinson's disease.
Clin Neuropharmacol. 1998 May; 21(3): 152-158.
PMID: 9617506; UI: 98280500.

 Piercey MF.           
Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in
treating Parkinson's disease.
Clin Neuropharmacol. 1998 May; 21(3): 141-151.
PMID: 9617505; UI: 98280499.

 Briars R.           
Communication breakdown.
Nurs Stand. 1998 Apr 1; 12(28): 18. No abstract available.
PMID: 9616619; UI: 98279591.

 Kerschan K, et al.           
[No title available].
Wien Klin Wochenschr. 1998 Apr 24; 110(8): 279-286. German.
PMID: 9615959; UI: 98278193.

 Mandel RJ, et al.           
Characterization of intrastriatal recombinant adeno-associated virus-mediated
gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in
a rat model of Parkinson's disease.
J Neurosci. 1998 Jun 1; 18(11): 4271-4284.
PMID: 9592104; UI: 98256394.

 Fox SH, et al.           
Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona
reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Exp Neurol. 1998 May; 151(1): 35-49.
PMID: 9582253; UI: 98250832.

 Mandanas L.           
Management of Parkinson disease.
J Am Board Fam Pract. 1998 Mar; 11(2): 171. No abstract available.
PMID: 9542714; UI: 98203841.

 Boraud T, et al.           
Effects of L-DOPA on neuronal activity of the globus pallidus externalis (GPe)
and globus pallidus internalis (GPi) in the MPTP-treated monkey.
Brain Res. 1998 Mar 16; 787(1): 157-160.
PMID: 9518590; UI: 98186741.

 Zubenko GS, et al.           
Initial results of a genome survey for novel Alzheimer's disease risk genes:
association with a locus on the X chromosome.
Am J Med Genet. 1998 Mar 28; 81(2): 196-205.
PMID: 9613863; UI: 98273944.

 Kunugi H, et al.           
Association study of structural mutations of the tyrosine hydroxylase gene
with schizophrenia and Parkinson's disease.
Am J Med Genet. 1998 Mar 28; 81(2): 131-133.
PMID: 9613851; UI: 98273932.

 Meara J, et al.           
Sertraline for the treatment of depression in Parkinson's disease.
Mov Disord. 1998 May; 13(3): 622. No abstract available.
PMID: 9613775; UI: 98273831.

 Djaldetti R, et al.           
Extreme anticipation in young-onset Parkinson's disease.
Mov Disord. 1998 May; 13(3): 599-600. No abstract available.
PMID: 9613762; UI: 98273818.

 Fernandez HH, et al.           
Clozapine for dopaminergic-induced paraphilias in Parkinson's disease.
Mov Disord. 1998 May; 13(3): 597-598. No abstract available.
PMID: 9613761; UI: 98273817.

 Speelman JD, et al.           
Resurgence of functional neurosurgery for Parkinson's disease: a historical
perspective.
Mov Disord. 1998 May; 13(3): 582-588.
PMID: 9613759; UI: 98273815.

 Adler CH, et al.           
Olfactory function in restless legs syndrome.
Mov Disord. 1998 May; 13(3): 563-565.
PMID: 9613755; UI: 98273811.

 Caviness JN, et al.           
Cortical myoclonus in levodopa-responsive parkinsonism.
Mov Disord. 1998 May; 13(3): 540-544.
PMID: 9613750; UI: 98273806.

 O'Sullivan JD, et al.           
Apomorphine-induced penile erections in Parkinson's disease.
Mov Disord. 1998 May; 13(3): 536-539.
PMID: 9613749; UI: 98273805.

 Merello M, et al.           
Confirmation of the antidyskinetic effect of posteroventral pallidotomy by
means of an intraoperative apomorphine test.
Mov Disord. 1998 May; 13(3): 533-535.
PMID: 9613748; UI: 98273804.

 Pang CP, et al.           
Rarity of debrisoquine hydroxylase gene polymorphism in Chinese patients with
Parkinson's disease.
Mov Disord. 1998 May; 13(3): 529-532.
PMID: 9613747; UI: 98273803.

 Elble RJ.           
Tremor in ostensibly normal elderly people.
Mov Disord. 1998 May; 13(3): 457-464.
PMID: 9613737; UI: 98273793.

 Marti-Masso JF, et al.           
Cinnarizine-induced parkinsonism: ten years later.
Mov Disord. 1998 May; 13(3): 453-456.
PMID: 9613736; UI: 98273792.

 Delalande I, et al.           
Do visual-evoked potentials and spatiotemporal contrast sensitivity help to
distinguish idiopathic Parkinson's disease and multiple system atrophy?
Mov Disord. 1998 May; 13(3): 446-452.
PMID: 9613735; UI: 98273791.

 Wenning GK, et al.           
123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's
disease.
Mov Disord. 1998 May; 13(3): 438-445.
PMID: 9613734; UI: 98273790.

 Hausdorff JM, et al.           
Gait variability and basal ganglia disorders: stride-to-stride variations of
gait cycle timing in Parkinson's disease and Huntington's disease.
Mov Disord. 1998 May; 13(3): 428-437.
PMID: 9613733; UI: 98273789.

 Oliveira RM, et al.           
Hypometria in Parkinson's disease: automatic versus controlled processing.
Mov Disord. 1998 May; 13(3): 422-427.
PMID: 9613732; UI: 98273788.

 Agostino R, et al.           
Clinical impairment of sequential finger movements in Parkinson's disease.
Mov Disord. 1998 May; 13(3): 418-421.
PMID: 9613731; UI: 98273787.

 Verhagen Metman L, et al.           
A trial of dextromethorphan in parkinsonian patients with motor response
complications.
Mov Disord. 1998 May; 13(3): 414-417.
PMID: 9613730; UI: 98273786.

 Chrischilles EA, et al.           
The health burdens of Parkinson's disease.
Mov Disord. 1998 May; 13(3): 406-413.
PMID: 9613729; UI: 98273785.

 Chio A, et al.           
Prevalence of Parkinson's disease in Northwestern Italy: comparison of tracer
methodology and clinical ascertainment of cases.
Mov Disord. 1998 May; 13(3): 400-405.
PMID: 9613728; UI: 98273784.

 Potagas C, et al.           
Clinical assessment of olfactory dysfunction in Parkinson's disease.
Mov Disord. 1998 May; 13(3): 394-399.
PMID: 9613727; UI: 98273783.

 Kordower JH, et al.           
Fetal nigral grafts survive and mediate clinical benefit in a patient with
Parkinson's disease.
Mov Disord. 1998 May; 13(3): 383-393.
PMID: 9613726; UI: 98273782.

 Trosch RM, et al.           
Clozapine use in Parkinson's disease: a retrospective analysis of a large
multicentered clinical experience.
Mov Disord. 1998 May; 13(3): 377-382.
PMID: 9613725; UI: 98273781.

 Kordower JH, et al.           
Neuropathology of fetal nigral grafts in patients with Parkinson's disease.
Mov Disord. 1998; 13 Suppl 1: 88-95. No abstract available.
PMID: 9613724; UI: 98273780.

 Lindvall O.           
Update on fetal transplantation: the Swedish experience.
Mov Disord. 1998; 13 Suppl 1: 83-87.
PMID: 9613723; UI: 98273779.

 Kumar R, et al.           
Pallidotomy and deep brain stimulation of the pallidum and subthalamic nucleus
in advanced Parkinson's disease.
Mov Disord. 1998; 13 Suppl 1: 73-82.
PMID: 9613722; UI: 98273778.

 Kang UJ.           
Potential of gene therapy for Parkinson's disease: neurobiologic issues and
new developments in gene transfer methodologies.
Mov Disord. 1998; 13 Suppl 1: 59-72.
PMID: 9613721; UI: 98273777.

 Olanow CW, et al.           
Current status of selegiline as a neuroprotective agent in Parkinson's
disease.
Mov Disord. 1998; 13 Suppl 1: 55-58. No abstract available.
PMID: 9613720; UI: 98273776.

 Lapchak PA.           
A preclinical development strategy designed to optimize the use of glial cell
line-derived neurotrophic factor in the treatment of Parkinson's disease.
Mov Disord. 1998; 13 Suppl 1: 49-54.
PMID: 9613719; UI: 98273775.

 Shoulson I.           
Where do we stand on neuroprotection? Where do we go from here?
Mov Disord. 1998; 13 Suppl 1: 46-48.
PMID: 9613718; UI: 98273774.

 Hirsch EC, et al.           
Iron metabolism and Parkinson's disease.
Mov Disord. 1998; 13 Suppl 1: 39-45.
PMID: 9613717; UI: 98273773.

 Przedborski S, et al.           
Mechanisms of MPTP toxicity.
Mov Disord. 1998; 13 Suppl 1: 35-38.
PMID: 9613716; UI: 98273772.

 Jenner P.           
Oxidative mechanisms in nigral cell death in Parkinson's disease.
Mov Disord. 1998; 13 Suppl 1: 24-34.
PMID: 9613715; UI: 98273771.

 Burke RE.           
Programmed cell death and Parkinson's disease.
Mov Disord. 1998; 13 Suppl 1: 17-23. No abstract available.
PMID: 9613714; UI: 98273770.

 Logroscino G, et al.           
Dietary iron, animal fats, and risk of Parkinson's disease.
Mov Disord. 1998; 13 Suppl 1: 13-16.
PMID: 9613713; UI: 98273769.

 Duvoisin RC.           
Role of genetics in the cause of Parkinson's disease.
Mov Disord. 1998; 13 Suppl 1: 7-12. No abstract available.
PMID: 9613712; UI: 98273768.

 Fahn S, et al.           
Highlights of the Parkinson's Disease Foundation.
Mov Disord. 1998; 13 Suppl 1: 2-6. No abstract available.
PMID: 9613711; UI: 98273767.

 Braune S, et al.           
Impaired cardiac uptake of meta-[123I]iodobenzylguanidine in Parkinson's
disease with autonomic failure.
Acta Neurol Scand. 1998 May; 97(5): 307-314.
PMID: 9613560; UI: 98273616.

 Iwasa K, et al.           
Decreased myocardial 123I-MIBG uptake in Parkinson's disease.
Acta Neurol Scand. 1998 May; 97(5): 303-306.
PMID: 9613559; UI: 98273615.

 Zipp F, et al.           
Glutamine synthetase activity in patients with Parkinson's disease.
Acta Neurol Scand. 1998 May; 97(5): 300-302.
PMID: 9613558; UI: 98273614.

 Pierelli F, et al.           
Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian
patients.
Acta Neurol Scand. 1998 May; 97(5): 295-299.
PMID: 9613557; UI: 98273613.

 Rubenstein LM, et al.           
The usefulness of the Functional Status Questionnaire and Medical Outcomes
Study Short Form in Parkinson's disease research.
Qual Life Res. 1998 May; 7(4): 279-290.
PMID: 9610212; UI: 98273132.

 Losonczy KG, et al.           
Prevalence and correlates of dementia: survey of the last days of life.
Public Health. 1998 May; 113(3): 273-280.
PMID: 9610210; UI: 98273130.

 Yokoyama T, et al.           
Localizing pallidotomy lesions.
J Neurosurg. 1998 Jun; 88(6): 1125-1126. No abstract available.
PMID: 9609317; UI: 98270480.

 Chodakiewitz JW.           
Localizing pallidotomy lesions.
J Neurosurg. 1998 Jun; 88(6): 1125. No abstract available.
PMID: 9609316; UI: 98270479.

 Ross DA.           
Thalamotomy for parkinsonian tremor.
J Neurosurg. 1998 Jun; 88(6): 1121-1122. No abstract available.
PMID: 9609313; UI: 98270476.

 Mehta V, et al.           
Enhancement of graft survival and sensorimotor behavioral recovery in rats
undergoing transplantation with dopaminergic cells exposed to glial cell line-
derived neurotrophic factor.
J Neurosurg. 1998 Jun; 88(6): 1088-1095.
PMID: 9609305; UI: 98270468.

 Duma CM, et al.           
Gamma knife radiosurgery for thalamotomy in parkinsonian tremor: a five-year
experience.
J Neurosurg. 1998 Jun; 88(6): 1044-1049.
PMID: 9609299; UI: 98270462.

 Vitek JL, et al.           
Microelectrode-guided pallidotomy: technical approach and its application in
medically intractable Parkinson's disease.
J Neurosurg. 1998 Jun; 88(6): 1027-1043.
PMID: 9609298; UI: 98270461.

 Yoshida K, et al.           
Single and repeated electroconvulsive shocks activate dopaminergic and
5-hydroxytryptaminergic neurotransmission in the frontal cortex of rats.
Prog Neuropsychopharmacol Biol Psychiatry. 1998 Feb; 22(2): 435-444.
PMID: 9608612; UI: 98271539.

 Parsa MA, et al.           
Quetiapine (Seroquel) in the treatment of psychosis in patients with
Parkinson's disease.
J Neuropsychiatry Clin Neurosci. 1998; 10(2): 216-219.
PMID: 9608412; UI: 98271339.

 Roane DM, et al.           
Delusional misidentification in association with parkinsonism.
J Neuropsychiatry Clin Neurosci. 1998; 10(2): 194-198.
PMID: 9608408; UI: 98271335.

 Moellentine C, et al.           
Effectiveness of ECT in patients with parkinsonism.
J Neuropsychiatry Clin Neurosci. 1998; 10(2): 187-193.
PMID: 9608407; UI: 98271334.

 Imaoka T, et al.           
Significant behavioral recovery in Parkinson's disease model by direct
intracerebral gene transfer using continuous injection of a plasmid DNA-
liposome complex.
Hum Gene Ther. 1998 May 1; 9(7): 1093-1102.
PMID: 9607420; UI: 98268436.

 Zhuchenko TD, et al.           
[Vascular parkinsonism].
Zh Nevrol Psikhiatr Im S S Korsakova. 1998; 98(4): 62-65. Russian. No abstract
available.
PMID: 9606903; UI: 98269748.

 Baziian BKh, et al.           
[Possible mechanism of disturbances of saccadic eye movements in patients with
Parkinson disease].
Biull Eksp Biol Med. 1998 Mar; 125(3): 254-259. Russian. No abstract
available.
PMID: 9606536; UI: 98269381.

 Bourke D, et al.           
Possible association between donepezil and worsening Parkinson's disease.
Ann Pharmacother. 1998 May; 32(5): 610-611. No abstract available.
PMID: 9606486; UI: 98269331.

 Goldman WP, et al.           
Cognitive and motor functioning in Parkinson disease: subjects with and
without questionable dementia.
Arch Neurol. 1998 May; 55(5): 674-680.
PMID: 9605724; UI: 98266761.

 Kanemaru K, et al.           
Cerebrospinal fluid homovanillic acid levels are not reduced in early
corticobasal degeneration.
Neurosci Lett. 1998 Apr 3; 245(2): 121-122.
PMID: 9605500; UI: 98266537.

 Jin BK, et al.           
Melatonin protects nigral dopaminergic neurons from
1-methyl-4-phenylpyridinium (MPP+) neurotoxicity in rats.
Neurosci Lett. 1998 Apr 3; 245(2): 61-64.
PMID: 9605485; UI: 98266522.

 Rozas G, et al.           
Sprouting of the serotonergic afferents into striatum after selective lesion
of the dopaminergic system by MPTP in adult mice.
Neurosci Lett. 1998 Apr 10; 245(3): 151-154.
PMID: 9605478; UI: 98266515.

 Sandyk R.           
Reversal of a body image disorder (macrosomatognosia) in Parkinson's disease
by treatment with AC pulsed electromagnetic fields.
Int J Neurosci. 1998 Feb; 93(1-2): 43-54.
PMID: 9604168; UI: 98267527.

 Herishanu YO, et al.           
A case-referent study of extrapyramidal signs (preparkinsonism) in rural
communities of Israel.
Can J Neurol Sci. 1998 May; 25(2): 127-133.
PMID: 9604134; UI: 98267493.

 Spillantini MG, et al.           
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's
disease and dementia with lewy bodies.
Proc Natl Acad Sci U S A. 1998 May 26; 95(11): 6469-6473.
PMID: 9600990; UI: 98263381.

 Corrigan FM, et al.           
Diorthosubstituted polychlorinated biphenyls in caudate nucleus in Parkinson's
disease.
Exp Neurol. 1998 Apr; 150(2): 339-342.
PMID: 9527905; UI: 98197150.

 Palfi S, et al.           
MRI-stereotactical approach for neural grafting in basal ganglia disorders.
Exp Neurol. 1998 Apr; 150(2): 272-281.
PMID: 9527897; UI: 98197142.

 Hawkes CH, et al.           
Olfactory disorder in motor neuron disease.
Exp Neurol. 1998 Apr; 150(2): 248-253.
PMID: 9527894; UI: 98197139.

 Duty S, et al.           
Topographical organization of opioid peptide precursor gene expression
following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned
rat.
Exp Neurol. 1998 Apr; 150(2): 223-234.
PMID: 9527891; UI: 98197136.

 Maruyama W, et al.           
(-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from
apoptosis induced by peroxynitrite and nitric oxide.
J Neurochem. 1998 Jun; 70(6): 2510-2515.
PMID: 9603216; UI: 98264355.